Bictegravir/FTC/TAF

BIC/FTC/TAF is a single-tablet triple combination regimen of bictegravir, emtricitabine and tenofovir alafenamide, indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents.

Regimen Advantages

Bictegravir is a potent second-generation integrase strand transfer inhibitor with a high genetic barrier; TAF delivers comparable efficacy with significantly reduced renal and bone density impact; one tablet daily supports adherence.

Clinical Benefits

• Virologic suppression (HIV-1 RNA<50 c/mL) exceeding 92% in treatment-naive patients
• 48-week efficacy comparable to prior standards with better tolerability
• Fewer drug interactions and broad applicability

Dosing Information

Prescription only, to be prescribed by physicians experienced in antiretroviral therapy, with regular viral load monitoring. Refer to the approved package insert.